See this page online at: http://www.bioscienceworld.ca/Development
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
April 07 2011
Government of Canada invests in better treatment for Hepatitis C Patients with Hepatitis C or liver cancer may soon benefit from a novel drug delivery system leading to a safer and more effective treatment, thanks to an investment from the Government of Canada in Therapure Biopharma Inc.
|
|
February 22 2011
Merck Canada invests $5 million in Quebec Consortium for Drug Discovery to support biopharmaceutical research Merck Canada has renewed its partnership with the Quebec Consortium for Drug Discovery (CQDM) by investing a further $5 million over five years in the organization so it can continue its support of biopharmaceutical research in Quebec.
|
|
February 16 2011
Amorfix Alzheimer’s test detects aggregated beta amyloid in spinal fluid Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, announces preliminary results indicating that their human Alzheimer’s disease (AD) diagnostic assay can detect a signal from aggregated beta amyloid in the spinal fluid (CSF) from AD patients.
|
|
January 24 2011
Carleton professor leads team to investigate mysteries behind killer bird disease Avian cholera is the most critical infectious disease affecting wild North American waterfowl. The Natural Sciences and Engineering Research Council of Canada (NSERC) has just awarded Carleton University Professor Mark Forbes and a team of researchers more than half a million dollars over the next three years to study this bacterial disease in Arctic breeding waterfowl.
|
|
November 08 2010
Number of individuals with asthma in Ontario increases A new study in the American Journal of Epidemiology, led by Sunnybrook Health Sciences Centre researcher and Respirologist, Dr. Andrea Gershon and The Hospital for Sick Children (SickKids) researcher, Dr. Teresa To, suggests that there has been a startling increase in the number of people living with asthma in Ontario since 1996.
|
|
September 27 2010
Queen's researchers locate impulse control centre in the brain Impulsive behaviour can be improved with training and the improvement is marked by specific brain changes, according to a new Queen’s University study.
|
|
September 27 2010
New program announced looking for emerging Canadian scientists The mission of the McLaughlin-Rotman Centre for Global Health is to develop and evaluate new models of global health innovation and facilitate their adoption where they are most urgently needed.
|
|
September 14 2010
Stem Cell Therapeutics completes further analysis of stroke data Stem Cell Therapeutics Corp. announces that further analyses of the modified REGENESIS stroke data base have been completed.
|
|
August 12 2010
Funding supports study of breast cancer gene mutation A team of Queen’s University researchers receives $450,000 to study a gene mutation common to breast cancer patients.
|
|
July 29 2010
CIHR funding boosts Queen's research into breast cancer treatment Peter Greer (Pathology and Molecular Medicine, Queen's University) receives $1.6 million for two research projects aimed at developing new treatments to slow tumour growth in breast cancer.
|
|
July 07 2010
ELLICSR opens its doors The Electronic Living Lab for Interdisciplinary Cancer Survivorship Research (ELLICSR) officially opened last month, an event that was attended by UHN and surrounding community members. The 12,000 square foot research centre located at the Toronto General Hospital, was made possible by grants from the Canada Foundation for Innovation (CFI) ($1.2 million) and the Ontario Research Fund ($1.2 million). With additional support, the total project was $3.7 million.
|
|
June 22 2010
Artificial pancreas can prevent the development of hypoglycemia An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes. Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.
|
|
May 17 2010
Steve Scherer to lead $50M genomic medicine program at Toronto's McLaughlin Centre The University of Toronto has announced geneticist Dr. Steve Scherer as the new director of the McLaughlin Centre. This new phase of what was previously known as the McLaughlin Centre for Molecular Medicine will emphasize the advancement of genomic medicine through research and education. The centre was established in 2000 with a $50-million dollar bequest from the R Samuel McLaughlin Foundation.
|
|
April 21 2010
Immunovaccine signs licensing deal with Pfizer Animal Health Immunovaccine Inc. announces that Pfizer Animal Health, a business of Pfizer Inc., will exercise a licensing option on the company’s vaccine enhancement and delivery platform to develop a third livestock vaccine.
|
|
April 21 2010
Bio-Processing Alliance Inc. launches comprehensive consulting business Bio-Processing Alliance Inc. (BPAI) announces it has officially launched its business.
|
|
April 20 2010
Chemaphor project will receive share of new federal investment Chemaphor Inc. will receive a share of federal investment in R&D growth in Atlantic Canada.
|
|
April 20 2010
Chemaphor project will receive share of new federal investment Chemaphor Inc. will receive a share of federal investment in R&D growth in Atlantic Canada.
|
|
April 20 2010
Warnex Medical Laboratories recognized for quality Warnex Inc. announces its Medical Laboratories division has successfully renewed its laboratory accreditation by COLA, a U.S. healthcare accreditation organization.
|
|
April 16 2010
International Cancer Genome Consortium plans to sequence 25,000 cancer genomes The International Cancer Genome Consortium (ICGC) has set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The document outlines research design and projects as well as the important ethical framework for this science. The ICGC also announced that new members have joined the consortium.
|
|
March 12 2010
McGill, Quebec biotech firm partner for new bone-disease treatment Enobia Pharma taps McGill expertise in developing first effective treatment for rare genetic disorder.
|
|
March 12 2010
Trillium expands immunology pipeline, enters stem cell field Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, ON, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.
|
|
March 12 2010
Mount Sinai study finds clues to the causes of flesh-eating disease epidemics A team of collaborating scientists have sequenced almost 100 full genomes from three successive epidemics of flesh-eating bacteria.
|
|
February 19 2010
Funding injection for health research in Manitoba Newly announced funding from the Canadian Institutes of Health Research (CIHR) will provide a welcome injection to nine new projects at the University of Manitoba.
|
|
February 16 2010
YM Biosciences and NRC-BRI produce new breast cancer drug candidates YM BioSciences Inc. announced the first results of a collaborative program between YM and the National Research Council of Canada’s Biotechnology Research Institute (NRC-BRI).
|
|
January 26 2010
AlphaRx establishes corporate headquarters in Hong Kong and R&D facility in Shanghai AlphaRx Inc. has selected locations in Hong Kong and Shanghai for its corporate headquarters and a new R&D facility respectively. This initiative will spearhead a major push into Greater China.
|
|
January 22 2010
YM BioSciences and University of Toronto collaboration utilizes antibodies selectively targeting cancer cells YM BioSciences Inc. announces the results of its research collaboration with the University of Toronto, for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer.
|
|
January 08 2010
$59M supports infrastructure for 351 researchers across the country The Canada Foundation for Innovation (CFI) has announced $59 million in support for 262 projects in 40 Canadian research institutions, allowing 351 researchers to conduct cutting-edge research in world-class facilities.
|
|
December 18 2009
Pfizer and B.C. launch $9M collaboration to tackle cancer Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer.
|
|
September 10 2009
Cancer drug developer gets creditor protection after cash crunch Once promising cancer drug developer, Ambrilia Biopharma Inc. has been forced to file for bankruptcy protection under the Companies’ Creditors Arrangement Act.
|
|
September 10 2009
New facility to train hundreds more pharmacists for BC By: Life Sciences British Columbia
The province of British Columbia is investing $86.4 million in a new state-of-the-art building at the University of British Columbia that will house the Faculty of Pharmaceutical Science, enabling the expansion of the undergraduate program by 72 students, and helping address the shortage of pharmacists in B.C. |
|
July 20 2009
McGuinty Government invests in groundbreaking R&D for colorectal cancer Ontario is joining forces with Pfizer Inc. and leading Ontario research institutions to develop a new generation of drugs to fight colorectal cancer.
|
|
July 14 2009
Drug Developers convene in Vancouver to explore new commercialization approaches A unique drug development conference was hosted June 8 and 9 in Vacouver, BC.
|
|
July 14 2009
CQDM to invest $8 million in Quebec biopharmaceutical research Four projects have been selected from the first competition on drug discovery launched by the Quebec Consortium for Drug Discovery (CQDM) in the fall of 2008.
|
|
June 26 2009
Queens University physicists receive $10.5 million to find out the building blocks of universe Physicists at Queen’s University have received more than $10.5 million from the Canada Foundation for Innovation (CFI) to advance their underground research projects.
|
|
June 22 2009
Ontario Ministry of Research and Innovation announces $1.9 million investment At an announcement made at Trent University, the Ontario Ministry of Research and Innovation (MRI) pledged $1,979,661 to support the innovative research of Trent Forensic Science professor Dr. Barry Saville examining fungal diseases in crops to improve sustainability of agricultural production and ensure a more secure food supply for the people of Ontario.
|
|
June 22 2009
AEterna Zentaris to raise US$10 million from institutional investors Æterna Zentaris Inc. has received commitments to purchase US$10 million of units comprised of common shares and common share purchase warrants in a registered direct offering.
|
|
June 18 2009
U of S researchers conduct unique studies on childhood obesity University of Saskatchewan (U of S) researchers are delving deeper into reasons behind childhood obesity due to $665,000 in grants provided through a partnership involving the Canadian Institutes of Health Research (CIHR), Rx&D Health Research Foundation and the Heart and Stroke Foundation of Canada.
|
|
June 08 2009
Theratechnologies files new drug application Theratechnologies files a New Drug Application (“NDA”) with the US Food and Drug Administration (“FDA”) for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
|
|
May 25 2009
Stem Cell Therapeutics announces issuance of additional US patent Stem Cell Therapeutics (SCT) has been granted intellectual property protection in the United States covering use of prolactin for producing oligodendrocytes and treating demyelinating disease, patent No. 7,534,765, entitled "Pregnancy Induced Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin".
|
|
May 25 2009
Oncolytics Biotech Inc. completes patient enrolment in U.S. Phase II Sarcoma study Oncolytics Biotech Inc. has successfully completed patient enrolment in its multi-centre Phase II clinical trial to evaluate the intravenous administration of REOLYSIN® in patients with various sarcomas that have metastasized to the lung. A total of 52 patients have been enrolled in the trial.
|
|
May 08 2009
Inimex Pharmaceuticals begins first clinical study of an innate defense regulator Inimex Pharmaceuticals announces that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase I safety study of IMX942 being performed for Inimex in Montreal with the approval of Health Canada.
|
|
April 27 2009
Theratechnologies presents additional data Theratechnologies announces results from a pooled analysis from both its Phase III clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV patients with lipodystrophy were presented today at the 18th Annual Canadian Conference on HIV/AIDS Research in Vancouver.
|
|
April 27 2009
Lorus Therapeutics announces presentation of new supportive data for LOR-2040 Lorus Therapeutics Inc. announces the presentation by investigators at Ohio State University (OSU) of results for Lorus' lead clinical drug candidate LOR-2040, formerly known as GTI-2040, at the 100th Annual Meeting of the AACR in Denver, CO earlier this month.
|
|
April 27 2009
Amorfix and BioMosaics announce collaboration Amorfix Life Sciences Ltd. and BioMosaics Inc. announce a collaboration to develop and commercialize a blood-based assay for early detection of hepatocellular carcinoma (HCC) or primary liver cancer.
|
|
April 14 2009
Schulich Heart Centre first Sunnybrook’s Schulich Heart Centre’s cardiologists are the first in the country to implant a heart monitor that will improve diagnosis in patients with potential heart problems.
|
|
April 14 2009
CTT launches new website Canada’s Technology Triangle (CTT) launches its new website at www.techtriangle.com in an effort to attract investors to the Waterloo, ON Region.
|
|
April 09 2009
New director for School of Nursing at Memorial Dr. Judith McFetridge-Durdle has been appointed as the new director of Memorial’s School of Nursing. The appointment was approved at the Board of Regents March 31 meeting. Dr. McFetridge-Durdle will begin her term as director on Aug. 1, 2009.
|
|
March 30 2009
Neuromed announces Exalgo™ extended release tablets meets primary efficacy endpoint in phase III trial Neuromed Pharmaceuticals, Inc. announces positive results of a pivotal phase III clinical trial of its lead investigational drug, Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) (previously NMED-1077 and OROS(R) Hydromorphone).
|
|
March 27 2009
Osta announces promising human prostate tissue biopsy pathology results Osta Biotechnologies Inc. releases the results of a prostate cancer tissue biopsy study on its target for prostate cancer.
|
|
March 16 2009
Econiche™ vaccine shows 92% reduction in colonization of E. coli O157 in vaccinated cattle Bioniche Life Sciences Inc. announces that the results of a large-scale commercial beef feedlot study with the company’s E. coli O157 vaccine –EconicheTM - have been published in this month’s issue of Foodborne Pathogens and Disease (Vol. 6, Number 2, 2009), a peer-reviewed scientific journal.
|
|
March 16 2009
Medicure announces regulatory approval of Phase II clinical trial of Avastrem Medicure Inc. receives Health Canada, Therapeutic Products Directorate approval for a Phase II clinical study of Avastrem(TM) for the treatment of tardive dyskinesia (TD). The company anticipates enrollment to begin this month.
|
|
March 16 2009
Paladin files new drug submission Paladin Labs Inc. files a new drug submission for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension). Trelstar(R) 22.5 mg is a six month slow release, injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer.
|
|
March 16 2009
Researchers close to turning urine into water Queen’s University researchers are one step closer to turning human urine into drinking water. Developed for use in space, this discovery could allow for longer missions and larger crews.
|
|
March 02 2009
Stem Cell Therapeutics final Phase IIa BETAS safety trial results Stem Cell Therapeutics Corp. presents the complete positive results of the Phase IIa BETAS trial conducted by Drs. Steven Cramer, Michael Hill and David Brown at the International Stroke Conference, Feb. 19, 2009 in San Diego, CA.
|
|
March 02 2009
Transition Therapeutics announces completion of patient enrolment Transition Therapeutics Inc. announces the completion of patient enrolment for a Phase II clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes.
|
|
February 27 2009
Sunnybrook leads innovative efforts in pain control Findings show that over 30% of all patients suffer severe pain after surgery, which can lead to poor recovery and chronic pain. Uncontrolled pain can also potentially produce damaging effects on the heart and lungs.
|
|
February 27 2009
Long-term care facilities short on infection prevention, study shows Infection prevention and control resources and programming in Canadian long-term care facilities fall short of recommended standards, a new Queen's University study shows.
|
|
February 18 2009
Canadian Arthritis Network to operate until 2012 The Canadian Arthritis Network (CAN), a member of the Networks of Centres of Excellence (NCE), will continue to receive nearly $4.1 million per year ($12.2 million total), until March 2012, when its 14-year-term ends.
|
|
February 13 2009
YM BioSciences receives clearance from Canadian regulatory authorities YM BioSciences Inc. receives clearance from Canadian regulatory authorities to initiate two Phase II, double-blind, randomized trials for nimotuzumab, its EGFR-targeting antibody, in combination with radiation-based treatments.
|
|
February 13 2009
Protox Therapeutics initiates double-blinded placebo Phase II study Protox Therapeutics Inc. announces the initiation of a double-blinded placebo controlled Phase II study of PRX302 (study name: TRIUMPH) in patients with benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
|
|
February 13 2009
Cytochroma initiates Phase I trial Cytochroma has initiated a Phase I trial of CTAP201 Injection in hemodialysis patients. CTAP201 Injection is being developed for the treatment of mild-to-moderate secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).
|
|
February 13 2009
Oncolytics granted 31st patent Oncolytics Biotech Inc. has been granted its 31st U.S. Patent, No. 7,476,382, entitled “Reovirus for the Treatment of Neoplasia.”
|
|
February 05 2009
Environmental contaminants may help beat breast cancer Simon Fraser University Faculty of Health Sciences researcher, Tim Beischlag, has found that environmental contaminants such as dioxins and polychlorinated biphenyls (PCBs), well known carcinogens, activate a key protein also found in the human body that can suppress breast cancer growth.
|
|
February 02 2009
Lorus Therapeutics publishes results from LOR-2040 study Lorus Therapeutics Inc., a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the publication of a new preclinical study for its lead drug LOR-2040, formerly known as GTI-2040.
|
|
February 02 2009
InNexus drug treats non-Hodgkin's in primates InNexus Biotechnology Inc. has completed a primate study it says confirms the effectinvess and safety of its treatment for non-Hodgkins lymphoma tumors.
|
|
February 02 2009
New research will help predict potentially fatal adverse reactions to specific children's drugs The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) is collecting data from nine of the country’s largest children’s hospitals and will perform large-scale genomic and proteomic studies to identify genes linked to certain adverse drug reactions (ADRs).
|
|
February 02 2009
BioMS drug fails mid-stage study Edmonton-based BioMS Medical Corp. announces results from MINDSET-01, an exploratory Phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS.
|
|
January 30 2009
Federal Budget 2009/2010: Promising initiatives overshadowed by cuts to Genome Canada The federal government presented its 2009 budget and with it came concerns of how it will impact science innovation in Canada.
|
|
January 19 2009
Wellcome Trust Centre for Human Genetics selects GenoLogics Solution to manage sequencing data GenoLogics announces that Wellcome Trust is deploying its lab and data management solution for genomics, including integrations to next generation sequencing platforms.
|
|
January 19 2009
Cytochroma initiates Phase I study Cytochroma initiates a Phase I trial of CTAP201 Injection in hemodialysis patients. CTAP201 Injection is being developed for the treatment of mild-to-moderate secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).
|
|
January 19 2009
YM Biosciences receives clearance to initiate randomized double-blind clinical trials YM BioSciences Inc. receives clearance from Canadian regulatory authorities to initiate two Phase II, double-blind, randomized trials for nimotuzumab, its EGFR-targeting antibody, in combination with radiation-based treatments.
|
|
January 14 2009
Allon Therapeutics announces milestones for 2009 Allon Therapeutics Inc. announces its 2009 milestones and confirmed that the company’s existing cash resources are sufficient to fund its business into 2011.
|
|
December 22 2008
Medicago announces expansion of manufacturing facility Medicago Inc. plans to invest $1.5 million to expand its manufacturing facility located in the Technology Park of Quebec City to optimize manufacturing activities and provide additional space to produce clinical grade material for human clinical trials.
|
|
December 12 2008
Æterna Zentaris completes patient recruitment for safety trial of Phase III program Æterna Zentaris Inc. reaches its goal of recruiting 500 patients for the safety study of the Phase III program in benign prostatic hyperplasia (BPH) with its flagship product candidate, cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist.
|
|
December 01 2008
Breast cancer gets nearly $4 million in grants in Quebec Due to its fundraising activities and continuous breast cancer awareness campaigns in Quebec over the past three years, the Quebec Breast Cancer Foundation (QBCF) announces that it will grant $4 million to nine breast cancer research teams.
|
|
December 01 2008
Urodynamix presents first data on use of NIRS and Transurethral microwave therapy Urodynamix Technologies Ltd. announces that a multinational team will present an abstract highlighting the use of Urodynamix's near infrared spectroscopy (NIRS) technology for non-invasive measurement of blood flow changes during minimally invasive treatments for benign prostatic hyperplasia (BPH).
|
|
November 28 2008
New network will improve HIV/AIDS treatment Simon Fraser University health sciences professor Robert Hogg, who is internationally known for his understanding of infectious diseases, will head Canada’s first nation-wide HIV/AIDS antiretroviral research network.
|
|
November 17 2008
YM BioSciences reports data from exploratory clinical trials YM BioSciences Inc. releases data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR).
|
|
November 17 2008
Cytochroma announces positive comparative data on CTA018 Cytochroma announces positive comparative data on a novel vitamin D analog, CTA018, at the 2008 Annual Meeting of the American Society of Nephrology (ASN) in Philadelphia.
|
|
November 17 2008
Æterna Zentaris reaches second stage of patient recruitment AEterna Zentaris Inc. enters the second stage of patient recruitment for its Phase II trial in endometrial cancer with AEZS- 108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin.
|
|
November 14 2008
Lorus successfully completes IND-enabling toxicology studies Lorus Therapeutics Inc. announces the successful completion of toxicology studies for its lead small molecule LOR-253 anticancer drug, formerly known as LT-253. LOR-253 represents a new targeted approach in cancer drug development, by inducing KLF4, a tumor suppressor factor that is reduced in a variety of important cancers.
|
|
November 03 2008
Oncolytics collaborators present positive Phase I/II combination Oncolytics Biotech Inc. achieves positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
|
|
October 30 2008
YM Biosciences reports Daiichi and Kuhnil enroll first patients in randomized Phase II gastric trial YM BioSciences Inc. announces that two of its licensees for nimotuzumab, Daiichi-Sankyo Co., Ltd. in Japan and Kuhnil Pharmaceutical Co. in Korea, advise that they have commenced the enrollment in an 80-patient Phase II randomized, open-label trial of nimotuzumab (400mg weekly until progression) plus irinotecan (150mg/m(2) biweekly until progression) compared to irinotecan alone in patients with advanced or recurrent gastric cancer who are refractory to 5-FU containing regimens.
|
|
October 20 2008
Miraculins announces enrollment of first patient in second pivotal prostate cancer study Miraculins Inc. announces the enrollment of its first patient in the second pivotal study for the company's P2V(TM) prostate cancer diagnostic test.
|
|
October 17 2008
MethylGene initiates Phase I clinical study for fungal infections MethylGene Inc. announces the administration of MGCD290 as a single agent to the first cohort of healthy adult volunteers in a Phase I clinical study. MGCD290.
|
|
October 07 2008
Sunnybrook campaign to confront the stigma of mental illness Sunnybrook Health Sciences Centre launches Let's Face This - Confront the Stigma of Mental Illness, an innovative web-based initiative to address the growing public health issue. Psychiatrists at Sunnybrook now estimate that mental illness personally affects more than 10 million Canadians.
|
|
October 07 2008
BioMS Medical’s Phase III U.S. multiple sclerosis trial receives positive safety review BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.
|
|
October 07 2008
Methylgene receives clinical trial approval from Health Canada MethylGene Inc. announces that Health Canada has approved the company's clinical trial application (CTA) for MGCD290, a fungal Hos2 histone deacetylase (HDAC) inhibitor to be used in combination with azoles for the treatment of fungal infections.
|
|
October 06 2008
Æterna Zentaris reaches 2nd stage of patient recruitment for Phase II Trial in ovarian cancer Æterna Zentaris Inc. enters the second stage of patient recruitment for its Phase II trial in ovarian cancer with AEZS- 108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin.
|
|
September 25 2008
Colds and flu cut by 1/3 in four-city trial of COLD-FX® CV Technologies Inc. announces preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot's effectiveness in seniors and cuts colds and flu by one-third.
|
|
September 25 2008
Lorus Therapeutics announces publication on drug levels and clearance rates for anticancer drug Lorus Therapeutics Inc announces a scientific publication by a clinical research team at The Ohio State University (OSU) College of Pharmacy entitled "Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase" (Drug Metabolism and Disposition 2008, July 24 Epub ahead of print).
|
|
September 22 2008
Ambrilia expands its Goserelin product offering with a novel one-month formulation Ambrilia Biopharma Inc. announces that it has succeeded in manufacturing a final one-month formulation of goserelin intended for the treatment of prostate cancer and several gynecological indications. The Company has already developed a proprietary, novel 3-month formulation of goserelin for which a Phase I/II clinical program in prostate cancer patients was initiated in July 2008.
|
|
September 22 2008
MethylGene exercises the right to convert MethylGene Inc. exercises its right to convert to a royalty stream and milestone arrangement with Celgene Corporation for MGCD0103 as provided under the license and collaboration agreement between the companies formed in January 2006.
|
|
September 22 2008
Stem Cell Therapeutics Corp. receives No Objection Letter Stem Cell Therapeutics Corp. receives a No Objection Letter (NOL) from Health Canada for the company supported, investigator led Phase IIa single centre, open label study to characterize the safety of human Chorionic Gonadotropin (hCG) & Erythropoietin (EPO) in severe traumatic brain injury (TBI).
|
|
September 19 2008
Queen’s oncologist to head national cancer research action group A renowned Queen's University cancer researcher is the new chair of the Research Action Group of the Canadian Partnership Against Cancer, and co-chair of the Canadian Cancer Research Alliance.
|
|
September 19 2008
Miraculins announces plans to advance gastric cancer program Miraculins Inc. completes the internal review of its gastric cancer program and has confirmed seven blood based protein biomarkers of interest for their potential to separate gastric cancer patients from non-gastric cancer patients.
|
|
September 08 2008
DiagnoCure receives approval DiagnoCure Oncology Laboratories receives the U.S. CLIA certification required for the company to launch its new laboratory developed PrevistageTM GCC Colorectal Cancer Staging Test. The sales team can now actively promote the test, and the company’s U.S. clinical laboratory can perform it and report patient results worldwide.
|
|
September 08 2008
Protox completes enrollment of Phase 2 BPH trial Protox Therapeutics Inc. completes enrollment of patients for its Phase II study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 1 million men in Canada and over 50 million men worldwide.
|
|
September 05 2008
BioMS Medical’s lead drug receives fast track designation from FDA BioMS Medical Corp. announces that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the company’s lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS).
|
|
August 29 2008
Biovail receives Canadian approval for Ralivia™ for the treatment of moderately severe pain Biovail Corporation receives an expanded indication for once-daily Ralivia(TM) - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada. Ralivia(TM) is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.
|
|
August 26 2008
OGI and Invitrogen bring epigenomics to the forefront in Genome 2.0 symposium The Ontario Genomics Institute (OGI) teamed up with Invitrogen Corporation, a California-based global leader in providing life sciences technology, recently to host Genome 2.0: New Frontiers in Epigenomics, a one-day symposium addressing epigenetic regulation of gene expression with a special focus on chromatin biology, DNA methylation, non-coding RNAs and technology development.
|
|
August 25 2008
Allon presents AL-108 human efficacy data at Alzheimer’s conference A potential new treatment for Alzheimer’s disease that reduces the classic Alzheimer’s ‘tangle’ pathology in mice has also improved specific memory function in humans with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease.
|
|
August 22 2008
Funding Opportunity for Genomics S&T Platform Operations Support OGI announces that Genome Canada has issued an RFA for Science and Technology Platform Operations Support for ongoing Competition III projects and projects that will be funded under the Competition in Applied Genomics Research in Bioproducts or Crops.
|
|
August 14 2008
Pharmacokinetics study confirms therapeutic-enabling quantities of Allon's drugs Allon Therapeutics Inc. announces that a pharmacokinetics study has confirmed that the company's clinical stage drugs AL-108 and AL-208 penetrate the blood brain barrier of healthy adults and Alzheimer's disease patients in sufficient quantities to enable a therapeutic effect on Alzheimer’s and other neurodegenerative diseases.
|
|
August 07 2008
Cytochroma and Mitsubishi Tanabe form partnership Cytochroma and Mitsubishi Tanabe Pharma Corporation announce that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and commercialize CTA018, Cytochroma’s novel vitamin D analog.
|
|
August 06 2008
Chemokine Therapeutics announces breast cancer data Chemokine Therapeutics Corp. announces that research results have been presented by the laboratory of Dr. Danny R. Welch, president of the Metastasis Research Society and Professor of Pathology, Cell Biology and Pharmacology, University of Alabama at Birmingham, at the Joint Metastasis Research Society (MRS) - American Association for Cancer Research (AACR) Conference on Metastasis held in Vancouver, BC.
|
|
August 06 2008
Lorus toxicology program supports novel route of administration of the anticancer drug LOR-2040 in bladder cancer Lorus Therapeutics Inc. announces the successful completion of GLP toxicology studies to explore a novel route of administration for its clinical-stage anticancer drug, LOR-2040.
|
|
August 06 2008
YM Biosciences reports Phase II data for nimotuzumab in metastatic colorectal cancer YM BioSciences Inc. releases preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC).
|
|
July 28 2008
Generex provides update on dosing of patients In Phase III trial Generex Biotechnology Corporation initiates dosing of over 100 patients in the Company’s pivotal Phase III clinical trial of, Generex Oral-lyn™, its flagship proprietary oral insulin spray product.
|
|
July 28 2008
Valens Pharma reports top-line results from voluntary Phase II trial Valens Pharma Ltd. announces preliminary results from its voluntary Phase II clinical trial evaluating its proprietary intravenous formulation of dichloroacetate (DCA i.v.) in high risk, geriatric patients undergoing open heart surgical procedures.
|
|
July 24 2008
Amorfix Life Sciences and Dr. Cashman receive Canadian government grant Amorfix Life Sciences and the University of British Columbia (UBC) announce a research collaboration to develop Alzheimer’s treatments based upon the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer’s Disease.
|
|
July 24 2008
Ambrilia initiates Phase I/II clinical program Ambrilia Biopharma Inc. initiates the Phase I/II clinical development program of its proprietary, novel three-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
|
|
July 14 2008
Stem Cell Therapeutics announces issuance of Keystone Prolactin patents Calgary based biotech company Stem Cell Therapeutics (SCT) Corp. has been issued two corresponding patents to strengthen its intellectual property landscape in the United States and Australia.
|
|
July 02 2008
Protox granted orphan status in Europe for brain cancer treatment Protox Therapeutics Inc. announces that following a positive opinion from the European Medicines Evaluation Agency's ("EMEA") Committee for Orphan Medicinal Products ("COMP"), the European Commission has granted Orphan designation to PRX321 for the treatment of glioma, a terminal brain cancer for which there is no known cure.
|
|
June 27 2008
Bioniche secures final financing Bioniche Life Sciences Inc. announces that it has secured an amendment to a pre-existing $7.6 million contribution agreement with the Industrial Technologies Office of Industry Canada that will support the scale-up of its vaccine production facility in Belleville, ON.
|
|
June 27 2008
Amorfix achieves target sensitivity with its Alzheimer’s disease diagnostic test Amorfix Life Sciences announces that its diagnostic test for the presence of aggregated Abeta in Alzheimer’s disease is ready to be applied to patient samples.
|
|
June 13 2008
Chemokine Therapeutics announces final results of Phase I/II clinical trial in late stage cancer patients Chemokine Therapeutics Corp. announces positive data following the successful completion of the Phase I/II clinical trial for CTCE-9908, the company's anti-cancer drug candidate.
|
|
June 13 2008
MethylGene initiates second Phase I clinical trial MethylGene Inc. announces the dosing of the first patient in a Phase I clinical trial evaluating MGCD265 in solid tumours (Trial 101). This is the second Phase I trial with the compound, which is being evaluated on different dosing schedules.
|
|
June 13 2008
Ambrilia reports positive final Phase III results Ambrilia Biopharma Inc. reports positive 24-week Phase III ("Study 301") top-line results for its proprietary prolonged-release formulation of Octreotide ("C2L").
|
|
June 02 2008
Patheon announces completion of York Mills facility sale The agreement to sell the facility for a purchase price of $12.5 million was entered into on December 31, 2007 as part of Patheon's global network restructuring plan.
|
|
June 02 2008
Chemokine Therapeutics announces issuance of two new U.S. patents Chemokine Therapeutics Corp. announces that it has been granted two U.S. Patents (No's 7,354,899 and 7,368,425).
|
|
June 02 2008
Stem Cell Therapeutics Corp. announces enrollment of the first patient in its REGENESIS Phase IIb stroke trial Stem Cell Therapeutics Corp. enrolls its first patient in the REGENESIS Phase IIb stroke trial. The REGENESIS trial is a double-blind, randomized, placebo-controlled Phase IIb clinical trial for SCT's lead program, NTx(TM)-265, for the treatment of acute ischemic stroke.
|
|
May 30 2008
Drug continues to look promising to fight early Alzheimer's Sunnybrook, together with British and Canadian researchers, has co-led the second phase of a study that suggests the drug Flurizan, at a higher dose, has the potential to safely modify and slow down the progression of Alzheimer's disease (AD) in its early stages.
|
|
May 16 2008
Allon data demonstrate AL-309 as a new neuropathy treatment Allon Therapeutics Inc. presents preclinical data that demonstrates the potential of the company’s proprietary product candidate AL-309 as a treatment for peripheral neuropathy. AL-309 is the lead candidate in Allon’s second neuroprotection technology platform, derived from Activity Dependent Neurotrophic Factor (ADNF).
|
|
May 16 2008
Chemokine Therapeutics announces liver cancer data presented at the AACR meeting Therapeutics Corp. announces research results, which were presented by Dr. Ronnie Poon, from the Department of Surgery, University of Hong Kong at the American Association for Cancer Research (AACR) Annual Meeting. The data showed a strong anti-tumour effect in a preclinical model of liver cancer.
|
|
May 05 2008
Protox announces positive long-term data from BPH study Protox Therapeutics Inc. announces positive results from its Phase I study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH).
|
|
May 05 2008
Stem Cell Therapeutics receives approval from FDA for its Phase IIb clinical stroke trial Stem Cell Therapeutics Corp. receives approval from the U.S. Food and Drug Administration (FDA) to allow its investigational new drug application (IND) for NTxTM-265 to proceed.
|
|
May 01 2008
ProMetic presents preclinical data for prostate and pancreatic cancer ProMetic Life Sciences Inc. announces results of three compounds in preclinical studies for prostrate and pancreatic cancer.
|
|
May 01 2008
MethylGene initiates Phase I clinical trial for multi-targeted kinase inhibitor MethylGene Inc. announces the dosing of its first patient in a Phase I clinical trial of MGCD265 in patients with solid tumour cancers.
|
|
April 21 2008
Theratechnologies’ last patient treated in the confirmatory study testing tesamorelin in HIV-associated lipodystrophy Theratechnologies announces that its last patient has completed 26 weeks of treatment in the confirmatory Phase III trial testing tesamorelin in HIV-associated lipodystrophy.
|
|
April 18 2008
BioMS Medical’s Phase III U.S. multiple sclerosis trial receives positive safety review BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the company's on-going MAESTRO-03 U.S. pivotal Phase III clinical trial of MBP8298.
|
|
April 07 2008
Med BioGene confirms high accuracy rate for LymphExpress Dx™ Med BioGene Inc. announces results from a recent study that confirms the previously demonstrated high accuracy rate of LymphExpress Dx™ v.1.0.
|
|
April 07 2008
Supratek's lead compound is granted Orphan Drug Designation Supratek Pharma Inc. announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SP1049C for the treatment of gastric cancer.
|
|
April 07 2008
Thallion provides update on Shigamabs® program Thallion Pharmaceuticals Inc. will defer the start date of its Phase II/III Shigamabs® clinical trial by an estimated six months based on both operational and strategic considerations.
|
|
April 07 2008
Axela presents data on novel detection of key cardiac Troponin complexes Axela Inc. and researchers from the Johns Hopkins University School of Medicine, presented initial work illustrating the novel ability of the dotLab(TM) System to measure Cardiac Troponin Complexes at the US HUPO meeting in Bethesda, Maryland.
|
|
March 31 2008
SemBioSys initiates toxicology study for safflower-produced insulin SemBioSys Genetics Inc. has initiated a toxicology study in animals to demonstrate the safety and comparability of its safflower-produced insulin to pharmaceutical grade human insulin.
|
|
March 24 2008
Cardiome announces positive Phase IIb results for oral vernakalant Cardiome Pharma Corp. announces positive interim clinical results from its Phase IIb study demonstrating statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo.
|
|
March 24 2008
Chemokine receives approval from Health Canada to commence Phase II study in liver cancer Chemokine Therapeutics Corp. announces that it has received a No Objection Letter from Health Canada allowing the company to begin a Phae II study in liver cancer with its lead drug candidate, CTCE-9908.
|
|
March 20 2008
Baxter presents latest clinical trial results of GAMMAGARD LIQUID Baxter International Inc. announces the preliminary results of a Phase I/II clinical trial, testing the subcutaneous infusion (under the skin) of GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] (IGIV) with Enhanze™ Technology.
|
|
March 10 2008
Allon’s Phase II clinical trial shows statistically significant efficacy on human cognition and memory Allon Therapeutics Inc. releases top-line results of a Phase IIa clinical trial showing that its drug AL-108 has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD).
|
|
March 10 2008
FDA approves PRISTIQ™ for the treatment of adult patients with major depressive disorder Wyeth Pharmaceuticals announces that the U.S. Food and Drug Administration has approved PRISTIQ™ to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping PRISTIQ™ to wholesalers beginning in the second quarter of 2008.
|
|
March 10 2008
Stem Cell announces positive results from the phase IIa BETAS stroke trial Stem Cell Therapeutics Corp. announces positive results from the investigator led BETAS Phase IIa, open label, safety trial.
|
|
March 07 2008
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.
|
|
February 28 2008
COLD-fX explores children's market CV Technologies Inc. announces positive safety results in a pilot clinical trial as the first step in developing a children's formulation of COLD-fX® - the # 1 selling cold and flu remedy in Canada.
|
|
February 25 2008
Biovail receives Canadian approval for Wellbutrin(R) XL Biovail Corporation receives a Notice of Compliance from the Therapeutic Products Directorate (TPD) for its supplemental New Drug Submission (sNDS) for a new indication for Wellbutrin(R) XL in Canada - the prevention of major depressive illness with an autumn-winter seasonal pattern.
|
|
February 25 2008
OncoGenex reports lead drug candidate OGX-011 achieves primary endpoint in Phase II OncoGenex Technologies Inc. announces that the company's lead cancer drug candidate, OGX-011, also referred to as custirsen, was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer.
|
|
February 22 2008
Allon to study AL-108 drug distribution in Alzheimer's patients Allon Therapeutics Inc. has expanded the scope of its ongoing clinical trial evaluating the pharmacokinetics of the company’s drug AL-108 by adding Alzheimer’s disease patients to the study.
|
|
February 22 2008
U of S VIDO to lead centre of excellence in vaccine commercialization and research The University of Saskatchewan will lead a $25.5-million national Centre of Excellence for Commercialization and Research aimed at fast-tracking vaccine development for diseases of major public health concern such as pandemic influenza, whooping cough, chlamydia, ‘mad cow’ disease and severe diarrheal diseases.
|
|
February 08 2008
Allon trial studies pharmacokinetics of AL-108 & AL-208 Allon Therapeutics Inc. commences dosing in a Phase I clinical trial to evaluate the pharmacokinetics of AL-108 or AL-208 in the blood and cerebrospinal fluid (CSF) of healthy adult subjects.
|
|
February 08 2008
Arius completes pre-IND meeting with FDA for lead CD44 Cancer Stem Cell Program Arius Research Inc. completes its pre-IND (Investigational New Drug) meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2, its lead CD44 Cancer Stem Cell Program.
|
|
January 30 2008
Regulators from United States and European Union ease process for orphan drugs The European Commission, the European Medicines Agency and the U.S. Food and Drug Administration said they have adopted a common application form for drugmakers seeking orphan designation for their medicines, a move aimed at spurring development of treatments for rare diseases.
|
|
January 24 2008
iCo Therapeutics releases positive update on iCo-009 program iCo Therapeutics Inc. releases a positive update on the company’s iCo-009 program, an oral reformulation of Amphotericin B (AmpB) for the treatment of systemic fungal infections and visceral leishmaniasis.
|
|
January 24 2008
Preclinical studies show Allon’s drug AL-108 impacts Alzheimer's pathology and behaviour Allon Therapeutics Inc. announces preclinical data, which demonstrates that the company’s drug AL-108 reduces the physical brain damage associated with pathological hallmarks of Alzheimer’s disease (AD) and improves the behavioural capacity to learn and retain memory.
|
|
January 24 2008
Ambrilia reports positive phase III preliminary results showing the efficacy of its prolonged-release formulation of Octreotide Ambrilia Biopharma Inc. reports preliminary phase III results for its proprietary prolonged-release formulation of Octreotide (C2L) in acromegaly patients.
|
|
January 24 2008
YM BioSciences provides update on AeroLEF clinical development program YM BioSciences Inc. announces that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the company that the phase II acute pain study (AP5) of AeroLEF, upon re-review of data from the IND submission, has been placed on clinical hold.
|
|
January 14 2008
Oncolytics announces filing of Phase I/II clinical trial with REOLYSIN® Oncolytics Biotech Inc. announces that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase I/II clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN®.
|
|
January 14 2008
GeneNews initiates patient sample accrual for validation studies of colon cancer blood test GeneNews Limited announces that it has started collecting patient samples for clinical validation studies of its lead product under development, ColonSentry.
|
|
January 11 2008
Medication risks to be focus of pioneering Ottawa Summit A Canadian-led, international initiative to improve patient safety, focusing on health risks from taking prescribed medications, will be launched at an Ottawa workshop next month.
|
|
January 04 2008
MethylGene files IND for MGCD265, multi-targeted kinase (C-MET) inhibitor for oncology MethylGene Inc. announces that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for MGCD265, its multi-targeted (c-MET) kinase inhibitor.
|
|
January 04 2008
Protox announces positive final results from BPH study Protox Therapeutics Inc. announces positive final results from its Phase I study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common condition among the aging male population.
|
|
December 21 2007
Oncolytics Biotech announces issuance of 25th U.S. patent Oncolytics Biotech Inc. announces that it has been granted U.S. patent 7,306,902 entitled "Oncolytic Viruses as Phenotyping Agents for Neoplasms".
|
|
December 21 2007
Bioniche receives government support to scale-up vaccine production in Ontario Bioniche Life Sciences Inc. receives $10 million in provincial government financing in support of its vaccine production facility scale-up in Belleville, ON.
|
|
December 21 2007
Allon Therapeutics completes dosing in phase II clinical trial in alzheimer's program Allon Therapeutics Inc. announces that it has completed patient dosing for its phase II clinical trial evaluating the safety and efficacy of the company’s proprietary drug candidate AL-108 in patients with amnestic mild cognitive impairment (aMCI), a precursor to alzheimer's disease (AD).
|
|
December 21 2007
YM BioSciences announces first cohort of colorectal cancer trial closed to accrual YM BioSciences Inc. announces that it has completed accrual in the first 50 patient cohort of its Phase II trial of nimotuzumab in combination with irinotecan for the treatment of colorectal cancer.
|
|
December 10 2007
Ambrilia appoints Dr. St-Pierre to its board of directors Ambrilia Biopharma Inc. announces that Jean-Paul St-Pierre, M.D., has joined the board of directors of the company.
|
|
December 07 2007
Bioniche recognized as one of the Top 10 Life Sciences Companies in Canada Bioniche Life Sciences Inc. announces that it has been recognized as one of Canada's Top 10 Life Sciences Companies for 2008. Bioniche was chosen by a group of distinguished venture capital investors based on the company’s attractiveness as an exceptional investment in Canada.
|
|
December 07 2007
Theratechnologies announces publication of its 26-week Phase III data Theratechnologies announces that the results from its first Phase III clinical trial, using tesamorelin (TH9507), have been published in the Dec. 6, 2007 New England Journal of Medicine.
|
|
December 04 2007
Sunnybrook revolutionizes chronic pain management in Canada A promising new development for the 20 to 30% of Canadians suffering from chronic pain is on the horizon. Sunnybrook is now using ultrasound guided procedures to manage this condition, making it the only academic health centre in Canada and one of only two in North America to do so.
|
|
November 26 2007
Medical Ventures' Metricath Gemini influences stent selection Medical Ventures Corp. releases physician feedback from GAAME (Gemini Angioplasty and Arterial Measurement Evaluation) trial, which shows Metricath Gemini's ability to influence vessel and stent size.
|
|
November 26 2007
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board BioMS Medical Corp. announces that the Data Safety Monitoring Board (DSMB) for the company’s Phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per protocol.
|
|
November 26 2007
Biovail confirms FDA Class 2 status for BVF-033 submission Biovail Corporation confirms that the U.S. Food and Drug Administration (FDA) has classified the response submitted by the company to the FDA action letter for BVF-033, its novel salt formulation of bupropion, as Class 2.
|
|
November 20 2007
Resverlogix Corp. - first ever therapy targets optic nerve head for glaucoma Resverlogix Corp. announces positive results from preliminary proof-of-concept studies for Resverlogix’s TGF-Beta Shield TM as a potential new therapy for the treatment of glaucoma.
|
|
November 12 2007
AEterna Zentaris to develop potential cancer treatment AEterna Zentaris is set to further develop three follow-up multi-targeted cytotoxic candidates to AEZS-112 as potential cancer treatment.
|
|
November 08 2007
Supratek Pharma announces the clearing of investigational new drug application for SP1049C Supratek Pharma Inc. announces that the U.S. Food and Drug Association (FDA) has cleared its investigational new drug application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract.
|
|
November 08 2007
DiagnoCure furthers development of diagnostic pipeline DiagnoCure Inc. announces the publication of new data regarding one of its proprietary prognostic tests for breast, colon and other potential cancers.
|
|
October 26 2007
Oncolytics Biotech Inc. collaborators to present positive interim results Phase Ia/Ib combination REOLYSIN®/radiation clinical trial for patients with advanced or metastatic cancers. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.
|
|
October 26 2007
ARIUS announces successful completion of toxicology study ARIUS announces cancer stem cell antibody program successfully completes first toxicology study. The lead antibody targeting novel epitope of CD44 has been found in breast, colon and prostate cancers.
|
|
October 26 2007
Phase I data for the Twinstrand Drug TST10088 presented at International Cancer Therapeutics Conference Twinstrand Therapeutics Inc. presented an abstract entitled, "Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumours", at the Molecular Targets and Cancer Therapeutics International Conference in San Francisco.
|
|
October 26 2007
Protox completes BPH trial recruitment and announces positive interim data Protox Therapeutics Inc. announces that it has completed recruitment of patients for its Phase 1 clinical trial evaluating PRX302 in males with benign prostatic hyperplasia (BPH). Protox reported positive interim data from this study indicating that PRX302 is safe, well tolerated and shows promising signs of therapeutic activity.
|
|
October 23 2007
Generex Biotechnology to collaborate with leading investigator at Rochester University on pandemic avian influenza vaccine Generex Biotechnology Corporation announces that its wholly-owned immunotherapy subsidiary, Antigen Express, Inc., has entered into an agreement with the University of Rochester as part of the Antigen Express efforts to develop a novel vaccine against the potentially pandemic avian influenza.
|
|
October 12 2007
WEX Pharmaceuticals results of post hoc analysis of Tectin™ clinical trial accepted for publication WEX Pharmaceuticals Inc. announces that the post hoc analysis of its WEX-014 trial, "Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study" is in press in the peer reviewed Journal of Pain and Symptom Management.
|
|
October 12 2007
Phase I data for the Twinstrand drug TST10088 to be presented at International Cancer Therapeutics Conference Twinstrand Therapeutics Inc. announces that an abstract entitled, "Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors", has been accepted for presentation at the Molecular Targets and Cancer Therapeutics International Conference to be held in San Francisco, California on Oct. 22-26, 2007.
|
|
October 11 2007
Amorfix develops two vaccines that extend life in Amyotrophic Lateral Sclerosis (ALS) animal model Amorfix Life Sciences presents the results from its vaccine development program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease, at the 132nd Annual Meeting of the American Neurological Association held in Washington, DC last week.
|
|
October 11 2007
Allon adds additional efficacy evidence and publishes important review of Alzheimer’s Allon Therapeutics Inc. announces that the journal Expert Opinions in Investigational Drugs recently published an expert review by Allon's scientific team of novel drugs in development for Alzheimer's disease.
|
|
October 01 2007
Cannasat Therapeutics and IntelGenx Corp. reach key milestone Cannasat Therapeutics Inc., a company specializing in the development of cannabinoid-based pharmaceutical products, announces the commencement of a Phase I clinical study of its lead product, CAT 310, a potential treatment for neuropathic pain.
|
|
October 01 2007
WEX Pharmaceuticals Inc. - two Canadian patents issued WEX Pharmaceuticals Inc. announces the official grant to the company of Canadian Patent No. 2,485,337 under the title, "Analgesic Composition and Method" and Canadian Patent No. 2,493,885 under the title, "Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Synergistically Analgesic Effect in Mammals".
|
|
October 01 2007
Ambrilia presents latest data on its novel HIV integrase inhibitors at the 47th ICAAC Ambrilia Biopharma Inc. presented new data on its novel series of HIV integrase inhibitors (pyrazolopyridine inhibitors), showing its potential synergies with some of the known integrase inhibitors (diketo acid inhibitors) currently in clinical development.
|
|
September 27 2007
MethylGene to present at BioContact Quebec MethylGene Inc. announces that Donald F. Corcoran, president and chief executive officer of MethylGene, will present at the BioContact Quebec 2007 Conference in Quebec City on Thursday, October 4, 2007. Corcoran will provide a general update on the company including its histone deacetylase and kinase programs.
|
|
September 27 2007
Twinstrand Therapeutics files IND application for Immuogen in ricin antidote study Twinstrand Therapeutics Inc. files an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for the immunization of humans with a benign ricin-like toxoid.
|
|
September 17 2007
Northern Lipids Inc. (NLI) builds clinical manufacturing facility Northern Lipids Inc. (NLI) has completed the renovation and build-out of its' new Burnaby facility.
|
|
September 17 2007
NRC Institute for Biological Sciences collaborates with ART to develop molecular imaging solutions ART Advanced Research Technologies Inc. announces that a collaboration agreement has been signed with the National Research Council of Canada's Institute for Biological Sciences ("NRC-IBS") for the development of client-oriented diagnostic applications using the Company's proprietary time domain technology, in the emerging discipline of molecular imaging.
|
|
September 17 2007
Biovail receives Canadian approval for Ralivia(TM) Biovail Corporation announces that the Therapeutic Products Directorate (TPD) Canada has issued a Notice of Compliance (NOC) for 100mg, 200mg and 300mg tablet strengths of Ralivia(TM), the Company's once-daily, extended-release formulation of tramadol hydrochloride indicated for the management of pain of moderate severity in patients who require continuous treatment for several days or more.
|
|
September 14 2007
Allon commences Phase II schizophrenia trial and updates clinical progress Allon Therapeutics Inc. announces that enrolment has commenced in a Phase II clinical trial evaluating Allon's product AL-108 as a treatment for schizophrenia-related cognitive impairment.
|
|
September 14 2007
Pilot study suggests Metriacath is effective in renal artery procedures Medical Ventures Corp. announces that its Metricath Libra® arterial and in-stent measurement system was shown in a pilot study to be effective for use in renal arteries, according to results shared at the New Cardiovascular Horizons (NCVH) conference in New Orleans.
|
|
September 04 2007
SemBioSys updates Apo AI development program SemBioSys Genetics Inc.updats a release issued on July 12, 2007 announcing that the company had achieved commercial levels of apolipoprotein AI (native Apo AI)and apolipoprotein AI(Milano) (Apo AI Milano) accumulation in safflower seed lines.
|
|
September 04 2007
Neuromed garners $53.5M in venture funds Neuromed Pharmaceuticals banks $53.3 million in Series E funds, bringing its total take in venture capital to $126 million. Much of that money has been earmarked for clinical trials, including a late-stage study of a newly licensed pain drug.
|
|
August 30 2007
Ambrilia reports positive results from Phase II study Ambrilia Biopharma Inc. reports positive top-line results from the first clinical study of its prolonged release formulation of Octreotide ("C2L") in acromegalic patients.
|
|
August 20 2007
Arius announces issuance of two U.S. patents Arius Research Inc. has been granted two U.S. patents for antibodies; one patent within the CD63 Program, which has been licensed to the company's partner Genentech, Inc. and a second patent within the carcinoembryonic antigen (CEA) Program.
|
|
August 20 2007
Neuromed announces that Merck & Co., Inc. discontinues development of pain drug candidate Neuromed Pharmaceuticals announces that Merck & Co., Inc. and Neuromed have decided to discontinue development of NMED-160 (also known as MK-6721), a Phase II compound for the treatment of chronic pain. A joint research collaboration will continue to evaluate alternate, earlier stage, therapeutic candidates.
|
|
August 20 2007
Novartis Pharmaceuticals Canada Inc. announces expanded Health Canada approval Novartis Pharmaceuticals Canada Inc. announces expanded Health Canada approval of Prexige(lumiracoxib) for the acute and chronic treatment of the signs and symptoms of osteoarthritis (OA) in adults.
|
|
July 31 2007
Government invests $14.7 million in Thunder Bay's Molecular Medicine Research Centre The Honourable Tony Clement, Minister of Health and Minister for FedNor, joined the Honourable Joe Comuzzi, MP for Thunder Bay-Superior North, in Thunder Bay to announce that the government plans to invest $14.7 million in the Thunder Bay Regional Health Sciences Centre (TBRHSC) for the establishment of a Molecular Medicine Research Centre.
|
|
July 31 2007
BioMS Medical's relapsing-remitting multiple sclerosis trial BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.
|
|
July 31 2007
Neurochem granted fast track designation Neurochem Inc. announces that the U.S. Food and Drug Administration (FDA) has designated the investigational product candidate, tramiprosate (ALZHEMED), as a Fast Track Product for the treatment of Alzheimer's disease.
|
|
July 25 2007
Miraculins announces final results of prostate cancer biomarker study Miraculins Inc., a Canadian biotechnology company dealing with the discovery and validation of cancer biomarkers, announces final results from its PCSC04 study.
|
|
July 23 2007
Arius begins toxicology program for lead anti-cancer Arius Research Inc. has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
|
|
July 23 2007
LifeCycle Pharma to initiate Phase II clinical trial of LCP-AtorFen LifeCycle Pharma A/S initiates a Phase II clinical trial program using LCP-AtorFen, a fixed-dose combination of atorvastatin and fenofibrate, for the treatment of high cholesterol levels. LCP-AtorFen will be a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG).
|
|
July 23 2007
Protox announces positive clinical data from prostate cancer study Protox Therapeutics Inc. announces positive top-line results from its Phase I clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer following radiation failure. The trial results indicate that PRX302 is safe and well tolerated and shows promising signs of therapeutic activity following a single intra-prostatic treatment.
|
|
July 13 2007
SemBioSys achieves critical APO AI milestone SemBioSys Genetics Inc. has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AIMilano (collectively referred to as Apo AI) in safflower seed lines. Apo AI is believed by many clinicians to be the basis for the next generation of cardiovascular drugs, which represented a $35 billion market in 2006.
|
|
July 06 2007
AEterna Zentaris presents detailed Phase I results for anti-cancer compound AEterna Zentaris Inc. presented a poster outlining detailed Phase I results for its targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog, AEZS-108 (formerly named AN-152 and ZEN-008), in female patients with cancers expressing LHRH receptors.
|
|
July 06 2007
Four week therapy with Transition Therapeutics' E1-I.N.T.(TM) leads to sustained reduction in blood glucose levels Transition Therapeutics Inc. announces the results from its exploratory Phase IIa clinical trial indicating that four weeks of daily treatments with gastrin-based therapy, E1-I.N.T.(TM), showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for 6 months post-treatment.
|
|
July 06 2007
Capital Health and University of Alberta launch Alberta's first Phase I clinical trials facility Following its recent pledge to increase research investment in Edmonton from $10 million to $75 million per year by 2010, the Northern Alberta Clinical Trials and Research Centre (NACTRC), a joint venture of the University of Alberta and Capital Health, is unveiling a new Phase I clinical trials facility within the Dr. Peter Crockford Clinical Investigation Unit (CIU) at Capital Health's University of Alberta Hospital.
|
|
July 05 2007
CIHR president resigns Dr Alan Bernstein, president of the Canadian Institutes of Health Research (CIHR) and regarded by many as Canada's top scientist has informed Tony Clement, the federal minister of health and CIHR's governing council that he will be resigning his position, effective Oct. 31, 2007.
|
|
June 29 2007
Amorfix presents vCJD blood test results from its commercial high-throughput platform Amorfix Life Sciences announces that Dr. Neil Cashman, chief scientific officer of Amorfix, presented an overview of the company's proprietary Epitope Protection (EP) technology for the in vitro detection of variant Creutzfeldt-Jacob Disease (vCJD) at the Transmissible Spongiform Encephalopathies (TSE) Conference held in Berlin, Germany.
|
|
June 29 2007
Sod turning celebration launches U of S International Vaccine Centre Representatives of all three levels of government and the Canada Foundation for Innovation turned the sod to launch construction of the International Vaccine Centre (InterVac) at the University of Saskatchewan, a $110.4-million project that will significantly enhance Canada's capacity to fight infectious disease in both animals and humans.
|
|
June 25 2007
Osta announces promising pre-clinical results on a new cancer drug Osta Biotechnologies Inc. announces the results of a pilot pre-clinical efficacy study on its lead anti-cancer therapeutic agent OB-24 in a human melanoma xenograft mouse model. Data from this pre-clinical study showed a statistically significant reduction in tumor volumes in groups treated with OB-24, compared to untreated groups and groups treated with dacarbazine.
|
|
June 25 2007
Allon Therapeutics presents at International CNS Disease Congress Allon Therapeutics Inc. was invited to present Allon's clinical progress and strategy for AL-108 at the 3rd Annual CNS Diseases Congress, which took place June 25th to 26th, in Boston. The presentation by Dr. Bruce Morimoto, Allon's VP of Drug Development, was titled 'Neuroprotection by AL-108, an Intranasal Peptide'.
|
|
June 25 2007
Senopsys and Patheon collaborate to develop palatable drug products Senopsys LLC, signs a collaboration agreement with Patheon Inc., a leading global provider of drug development and manufacturing services, to accelerate the development of palatable drug products. Through this collaboration, Senopsys clients will have access to prototype drug formulations manufactured by Patheon and Patheon will be able to offer its clients taste assessment and optimization services.
|
|
June 25 2007
LifeCycle Pharma to initiate Phase II clinical trial of LCP-Tacro for organ transplantation LifeCycle Pharma will initiate a Phase II clinical trial of LCP-Tacro for the prevention of organ rejection in kidney transplant patients following the update of its initial Investigational New Drug Application (IND) in the United States.
|
|
June 11 2007
Isotechnika receives approval to participation in Phase 3 European/Canadian clinical trial Isotechnika Inc. announces that it has received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 in patients suffering from moderate to severe psoriasis.
|
|
June 11 2007
Protox completes prostate cancer trial recruitment Protox Therapeutics Inc. completes recruitment of patients for its Phase I study of PRX302 to treat localized, recurrent prostate cancer. The company is on track to report top line data from this study by mid year.
|
|
June 11 2007
Allon Therapeutics confirms oral bioavailability of AL-309 Allon Therapeutics Inc. releases new data confirming that the company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.
|
|
June 11 2007
Viventia Biotech initiates patient treatment for Vicinium Phase II bladder cancer trial Viventia Biotech Inc. initiates patient treatment in its open-label Phase II clinical trial for Vicinium(TM), administered using intravesical instillation for the treatment of locally persistent non-invasive bladder cancer. The trial, which will initially enroll patients in Canada before expanding into the U.S., is expected to be fully enrolled by Q4 2007.
|
|
May 28 2007
BioMS Medical completes patient recruitment for multiple sclerosis trial BioMS Medical Corp has completed patient recruitment in its phase II clinical trial of MBP8298, for the treatment of relapsing-remitting MS (RRMS). The trial, named MINDSET-01, includes approximately 215 patients, and is being conducted at 24 trial sites in six countries across Europe.
|
|
May 28 2007
Spectrum Pharmaceuticals discloses Phase II data for Ozarelix Spectrum Pharmaceuticals Inc., a partner of Aeterna Zentaris, announces the release of phase II safety and efficacy data for Ozarelix, its prime drug candidate for the treatment of benign prostatic hypertrophy (BPH).
|
|
May 28 2007
Final data published in Phase I/II clinical trial of bladder cancer drug Viventia Biotech Inc., a privately held biopharmaceutical company has secured final data from its dose escalation Phase I/II clinical trial of Vicinium(TM) in patients with high risk, non-invasive bladder cancer.
|
|
May 11 2007
WEX files clinical trial application with Health Canada for Tectin WEX Pharmaceuticals Inc. files a clinical trial application with the Biologics and Genetics Therapies Directorate (BGTD) of Health Canada for Tectin(TM), the lead candidate in the company's Tetrodotoxin (TTX) technology platform.
|
|
May 11 2007
Resverlogix advances RVX-208 IND program to parallel human microdosing Resverlogix Corp. announces favourable results from previously announced toxicology studies, enabling Resverlogix to advance development timing on its RVX-208 Investigational New Drug (IND) program. The official IND enabling studies are now being initiated and the IND is targeted for submission during the third quarter of 2007.
|
|
April 25 2007
Inflazyme receives Helicon's statement regarding preliminary results of IPL455,903 in Phase 2a memory study Inflazyme Pharmaceuticals Ltd. receives a statement from Helicon Therapeutics of New York regarding the outcome of the proof of concept Phase 2a study with IPL455,903 (HT-0712) in Age Associated Memory Impairment (AAMI).
|
|
April 25 2007
BioMS Medical's pivotal multiple sclerosis trial receives positive interim safety analysis BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase II/III MAESTRO-01 trial of MBP8298 in patients with secondary progressive MS has completed a planned interim safety analysis and recommended that the trial continue as per the protocol.
|
|
April 25 2007
Resverlogix announces milestone ApoA-l/HDL proof of concept data Resverlogix Corp. releases pivotal proof-of-concept data in non-human primates for the NexVas PR program. Interim results from a long term study in adult African Green monkeys demonstrate that oral administration once daily of RVX-208 for 28 days increased the levels of serum ApoA-I and HDL-cholestero
|
|
April 25 2007
Stem Cell Therapeutics Corp. announces positive interim results Stem Cell Therapeutics Corp. announces positive interim results from its currently enrolling Phase IIa- Safety Trial study 'Beta-hCG + Erythropoietin in Acute Stroke'.
|
|
April 18 2007
A triumph over Eczema? According to in-vitro trials run by Allegiance Equity Corp., the anti-inflammatory and antibacterial nature of a key component of the companys drug Relieva, may make the drug useful in treating patients with Atopic Dermatitis, a form of eczema.
|
|
April 13 2007
Urodynamix Expands NIRS intra-abdominal pressure study Urodynamix Technologies Ltd. receives notification from Health Canada allowing the company to expand its clinical trial ('NIRS IAP Study') at the Foothills Medical Centre in Calgary. Under the approved protocol the company may enroll up to 70 intensive care unit ('ICU') patients and will monitor subjects continuously for up to seven days.
|
|
April 13 2007
PainCeptor pharma raises $24.4 M Series B investment round PainCeptor Pharma Corp., a pharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain has raised $24.4 million in a Series B investment round.
|
|
April 13 2007
BioMS Medical's pivotal multiple sclerosis trial receives positive interim safety analysis BioMS Medical Corp. announces that the independent Data Safety Monitoring Board (DSMB) for the company's pivotal phase II/III MAESTRO-01 trial of MBP8298 in patients with secondary progressive MS has completed a planned interim safety analysis and recommended that the trial continue as per the protocol.
|
|
April 12 2007
Proteins as Drugs: Overcoming Hurdles and Future Challenges This year, the Crossroad of Biotechnology will present the 12th edition of its annual conference, to be held at the Biotechnology Research Institute of the National Research Council (NRC-BRI), June 13-14.
|
|
April 12 2007
FDA approves Alexion's Soliris for all patients with PNH Alexion Pharmaceuticals, Inc. receives marketing approval from the U.S. Food and Drug Administration (FDA) for Soliris (eculizumab). Soliris is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, disabling and life-threatening blood disorder defined by chronic red blood cell destruction or hemolysis.
|
|
April 02 2007
Isotechnika's independent data monitoring committee conducts review Isotechnika Inc. announces that an independent data monitoring committee (DMC) has met and reviewed the interim data from the Phase 2b kidney transplant (PROMISE) trial.
|
|
April 02 2007
Funding announcement expands Trent University's role as centre for anti-viral development Peterborough, ON, MP Dean Del Mastro announces that the federal government will provide $2 million to support the next development phase of the International Consortium on Anti-Virals (ICAV), headquartered at Trent University.
|
|
March 30 2007
New cardioprotective drug could provide for post-bypass surgery heart health Stent thrombosis, restenosis and lifelong prescriptions. Millions of patients have discovered that the drug-coated stents used as part of their heart operations may be having more of a detrimental effect on their health than medical experts have ever publicly acknowledged.
|
|
March 19 2007
UBC researcher finds new way to treat devastating fungal infections Devastating blood-borne fungal infections that can be lethal for HIV/AIDS, cancer and organ transplant patients may be treated more successfully, thanks to a new drug delivery method developed by researchers at the University of British Columbia in Vancouver.
|
|
March 19 2007
Allon product AL-108 successful in Phase Ib clinical trial Allon Therapeutics Inc. announces that the results of the completed Phase Ib clinical trial of its product AL-108 met all of its objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderly subjects after seven days of dosing.
|
|
March 19 2007
Chemokine Therapeutics Corp. announces positive preliminary data Chemokine Therapeutics Corp. announces positive preliminary data and the successful completion of the dose-escalation portion of its Phase Ib/II clinical trial for CTCE-9908, the company's anti-cancer drug candidate.
|
|
March 16 2007
Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 Liponex Inc., a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called 'good cholesterol,' announces results of the Phase I/II Clinical Trial of its lead product, CRD5.
|
|
March 12 2007
Cytochroma Inc. completes $21 million in financing for vitamin D technologies Cytochroma Inc., a spin-off of Queen's University's PARTEQ Innovations, has secured Cdn$21 million in new financing to advance its product development programs targeting vitamin D deficiency and related diseases in chronic kidney disease.
|
|
March 12 2007
Bioanalytical Contract Research A Brief Commentary
Contract research may be described as a service sector within the scientific community that has silently contributed to modern day advancements in drug discovery and development. |
|
March 12 2007
Early Researcher Award Goes to Trent University Professor Trent University biology Professor Marguerite Xenopoulos was elated that she'd be able to further her research into the impact of climate change on freshwater ecosystems when she learned that she won a major Early Researcher Award, valued at $150,000, from the Ministry of Research and Innovation.
|
|
March 12 2007
Canadian Government to Invest in Vaccine Research Development Facility The Canadian government will invest in an ambitious new vaccine research and development facility at the University of Saskatchewan, which will significantly enhance Canada's capacity to develop vaccines for both humans and animals.
|
|
March 09 2007
Pain drug development booming, reports anesthesiologist The number of new drugs being developed to relieve neuropathic pain - a chronic, devastating condition affecting 3-8% of the population - has quadrupled over the past year and a half, a Queen's University study shows.
|
|
March 02 2007
Health Canada approves significant new medical claims for COLD-fX CV Technologies Inc. announces that Health Canada has approved wide-ranging new health claims for COLD-fX. After an extensive review, the Natural Health Products Directorate (NHPD) - Health Canada's division responsible for evaluating the safety, efficacy and quality of natural health products (NHPs) - has issued a product license and natural product number (NPN) for COLD-fX.
|
|
March 02 2007
BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial BioMS Medical Corp announces that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive MS.
|
|
February 19 2007
First-ever depression in the workplace study unveiled A first ever US-Canada Forum on Mental Health will bring scientists and business executives together from both countries to forge a 'cure and prevention strategy' for major mental illnesses.
|
|
February 19 2007
Zelos Therapeutics Ostabolin-CTM increases bone mineral density in Phase II trial Zelos Therapeutics Inc. announces top-line results from a Phase II study of its novel parathyroid hormone (PTH) analogue, Ostabolin-C, in postmenopausal women with osteoporosis. Ostabolin-C is cyclic PTH (1-31), a proprietary PTH analogue that has demonstrated strong bone building activity in preclinical studies and is in late stage clinical development for the treatment of osteoporosis.
|
|
February 05 2007
Canadian company's medical technology recognized as having dramatic and sustainable impact on society Amorfix Life Sciences Ltd. of Toronto has become the only Canadian recipient of 47 organizations from around the world to be named as a 'Technology Pioneer' by the World Economic Forum at its prestigious annual meeting in Davos, Switzerland in January.
|
|
February 02 2007
Quebec life sciences research sector gets $10 million boost AstraZeneca Canada Inc. will invest $10 million to expand its basic research centre located in the Saint-Laurent Technoparc in metropolitan Montreal. The investment builds on the company's long-standing commitment to research and development in Quebec, a commitment that has translated into more than $400 million for scientific research and development over the past ten years.
|
|
February 01 2007
Novartis contracts ProMetic's ligand technology ProMetic Biosciences Ltd., a UK subsidiary of Montreal, QC-based ProMetic Life Sciences Inc., has signed an agreement with Novartis Vaccines and Diagnostics GmbH & Co. to develop a synthetic-ligand affinity adsorbent for the purification of a recombinant protein vaccine.
|
|
February 01 2007
NRC to support Amorfix Alzheimer's test Amorfix Life Sciences Ltd. received a $322,000 contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support research and development of a proposed diagnostic test for Alzheimer's disease, EP-Atm.
|
|
February 01 2007
3M invests in Response Biomedical 3M Company has made an $8-million equity investment in Response Biomedical Corp. as part of an agreement to develop diagnostic products targeting hospital and community acquired infectious diseases using the Vancouver, BC-based company's RAMP® testing platform.
|
|
January 23 2007
Queens spin-off Cytochroma Inc. completes $21 million in financing for vitamin D technologies Cytochroma Inc., a spin-off company of Queens Universitys PARTEQ Innovations, has secured Cdn$21 million in new financing to advance its product development programs targeting vitamin D deficiency and related diseases in chronic kidney disease. The new funding will support clinical trials with three investigational new drug products, which are scheduled to begin in 2007.
|
|
January 23 2007
Investment by the CFI, government, confirm confidence in imaging research in London A $26,975,700 project will boost healthcare in London and allow for the continuation of leading-edge research in hybrid imaging.
|
|
January 23 2007
Keeping an eye on potential healthcare savings: up to $1.5 billion in cost savings from cataracts possible Treatments to reduce the number of cataract surgeries could save the Canadian healthcare system up to $1.5 billion, according to a new study at The University of Western Ontario.
|
|
January 15 2007
Celebrating 70 Years of improving the health of mothers and babies - Alberta Medical Association launches online history book The Alberta Medical Association (AMA) releases its online history book of the AMAs Committee on Reproductive Care (RCC), A Celebration of 70 Years of Vision and Action, now available at www.albertadoctors.org/rcc.
|
|
January 15 2007
Keeping an eye on potential healthcare savings: up to $1.5 billion in cost savings from cataracts possible Treatments to reduce the number of cataract surgeries could save the Canadian healthcare system up to $1.5 billion, according to a new study at The University of Western Ontario.
|
|
January 10 2007
UBC receives $26 million in CFI support The University of British Columbia (Vancouver, BC) was one of the largest recipients of funding announced in November by the federal Canada Foundation for Innovation (CFI).
|
|
January 10 2007
Ottawa U Researchers Honoured Nine researchers from the University of Ottawa have been recognized for their achievements by the Ontario government.
|
|
January 10 2007
Governments, private sector provide funding for tech start-ups The federal and Quebec governments have joined with several private sector partners to establish a capital investment fund for business creation and start-up in the province's technology sector.
|
|
January 10 2007
National Investment Key Factor In Successful R&D Regions Worldwide And Canada "We know that the countries and jurisdictions that invest in innovation, that tap the creativity of their people, that market their ideas most effectively, will be home to the most rewarding jobs, the strongest economies and the best quality of life."
-Ontario Premier Dalton McGuinty, Minister of Research and Innovation (October 7, 2005). |
|
January 09 2007
Bioniche E. coli O157 :H7 cattle vaccine authorized for field use in Canada Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, received authorization from the Canadian Food Inspection Agency (CFIA) to distribute its E. coli O157:H7 cattle vaccine to Canadian veterinarians under a Permit to Release Veterinary Biologics as specified in the Canadian Health of Animal Regulations.
|
|
December 12 2006
Xenon enters into anemia collaboration with Roche Xenon to receive $7 million for equity and could potentially receive $44 million from research funding and milestone payments.
|
|
December 04 2006
BioAxone Therapeutic study demonstrates positive interim results for spinal cord injury Six week follow up results of Phase I/IIa trial show safety, tolerability and neurological outcome of Cethrin®.
|
|
December 04 2006
National research project to improve drug safety in children receives grant from Pfizer Canada Inc. A major national research project, co-led by Drs. Bruce Carleton and Michael Hayden, to improve drug safety for children, receives a major contribution of $500,000 from Pfizer Canada Inc. The project, named Genotype-Specific Approaches to Therapy in Childhood (GATC), receives major funding from a Genome Canada/Genome BC-sponsored research program and is led from two research centres within the Child & Family Research Institute (CFRI) at BC Childrens Hospital.
|
|
November 27 2006
CIHR supports Ottawa Researchers The Canadian Institutes of Health Research have provided $13.8 million in grants and scholarships to the University of Ottawa and its affiliate research institutions, including the University of Ottawa Heart Institute, the Ottawa Health Research Institute, the Children's Hospital of Eastern Ontario and the University of Ottawa Institute for Mental Health Research.
|
|
November 27 2006
TrialStat, NewLab Clinical Research and Biotheragene form drug discovery development consortium TrialStat Corporation, a clinical data management on demand company, creates with NewLab Clinical Research Inc. and BioTheraGene Inc. the Newfoundland and Labrador Research Consortium (NLRC).
|
|
November 07 2006
Transition Therapeutics Inc. partners with Juvenile Diabetes Research Foundation Canada Transition Therapeutics Inc. has partnered with the Juvenile Diabetes Research Foundation Canada.
|
|
November 07 2006
Thermo Electron Corporation enters into collaborative R&D agreement Thermo Electron Corporation has entered into a collaborative research and development agreement with the Research in Immune Tolerance in Transplantation (RITT) program. The research will be conducted in the RITT Industrial BioDevelopment Laboratory at the Toronto General Hospital.
|
|
November 01 2006
Federal government strengthens therapeutic patent protection Canada has passed new regulations that provide greater intellectual property protection for the medicines being produced by the countrys biotechnology companies.
|
|
October 24 2006
Tobacco-grown protein begins to show therapeutic potential Studies with mice taking tobacco containing the human gene interleukin-10 have seen a drop in the production of proteins related to inflammatory bowel disease, pointing the way to treatment for ailments affecting more than 1 million people in North America.
|
|
October 03 2006
Fresenius Kabi And Sandoz International Partner To Develop Drug Fresenius Kabi and Sandoz International will be partnering to develop a second-generation biopharmaceutical drug.
|
|
October 03 2006
Diagnostic Kit Receives Canadian Regulatory Approval Health Canada has granted approval to Innovotech Inc.'s bioFILM PA antimicrobial sensitivity kit.
|
|
October 02 2006
Happy Mice Point to Depression Treatment By breeding mice that lack a specific gene, scientists at the Research Institute of the McGill University Health Centre have created permanently "cheerful" rodents.
|
|
October 02 2006
PharmaGap begins studies to support clinical trials of new cancer drug Dr Michael Adams of Queens University will undertake pharmacological studies to support the introduction of PhGalphal, a new drug compound being developed by PharmaGap for the treatment of cancer
|
|
September 13 2006
Network Funds Projects to Understand Prion Diseases PrioNet Canada, a federally funded Network of Centres of Excellence established in 2005 to develop strategies to eradicate prion diseases, recently announced 10 recipients of its first open call for project proposals.
|
|
September 13 2006
York Projects Receive CFI Support The Canada Foundation for Innovation has awarded researchers at York University more than $400,000 for equipment and renovations to support work in vision research and chemistry.
|
|
September 12 2006
New Sunscreen Heals Burns A newly created sunscreen may be effective at healing sunburn and preventing skin cancer.
|
|
September 11 2006
Pharmacogenomics and Information-based Medicine The discipline of pharmacogenomics is aimed at discovering patterns in DNA, RNA, protein expression and biomarker data that correlate with disease risk, disease progression and drug response (clinical outcome) in an individual or a group of patients.
|
|
September 08 2006
Program to Further Understanding of Genetic Interaction With new evidence suggesting that many hereditary diseases are not caused by a single gene, but rather by a number of genes failing to work together, the Canadian Institute for Advanced Research (CIAR) has brought together a diverse team of leading genetics researchers to help understand how these "genetic networks" succeed and fail.
|
|
August 09 2006
Fabry Disease Study Receives $100M Commitment A national study of Fabry disease, a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, has gained widespread government support.
|
|
August 09 2006
Ontario Researchers Seek to Combat Fetal Alcohol Disorders An interdisciplinary team of researchers has received approximately $1.5 million from the Canadian Institutes of Health Research (Ottawa, ON) to test whether fetal exposure to methanol, a contaminant found in many alcoholic beverages, plays an important role in causing the life-long learning and behavioural problems associated with Fetal Alcohol Spectrum Disorders (FASD).
|
|
August 09 2006
Alberta Team Shows Ultrasound May Regrow Teeth The toothless grin of a hockey player may soon be a thing of the past.
|
|
July 10 2006
Prion Discovery Could Lead to Test for Human Mad Cow Disease New research may soon lead to the development of a test that detects the human form of mad cow disease.
|
|
July 05 2006
CIHR Funds Vulnerable Population Research CIHR (Ottawa, ON) recently handed out 20 health research grants worth more than $14 million to projects studying health disparities among Canadas most vulnerable populations.
|
|
July 04 2006
Ottawa Student Wins Sanofi-Aventis Biotech Challenge A Grade 10 health class discussion about the HIV-AIDS virus sparked a curiosity in James McLeod that resulted in his receiving top honours in the 2006 National Sanofi-Aventis Biotech Challenge.
|
|
July 04 2006
Samuel Lunenfeld Research Institute Receives $1M The Samuel Lunenfeld Research Institute (SLRI) (Toronto, ON) has secured funding to help support the next generation of scientists.
|
|
May 31 2006
Canadian Light Source Publishes Two Papers, Receives $6.2M for Beamline The University of Saskatchewan's (U of S) (Saskatoon, SK) Canadian Light Source Inc. (CLS) achieved a major milestone with the inaugural publication of two research papers.
|
|
May 31 2006
Science Fair Honours Young Researchers Forty Toronto-area students were honoured recently at the York Region Sci-Tech Fair.
|
|
May 31 2006
CIHR Awards $273M The Canadian Institutes of Health Research (CIHR) (Ottawa, ON) recently announced a large round of funding, awarding more than 793 grants and $273 million to researchers across Canada.
|
|
May 31 2006
2006 Killam Prizes Awarded The 2006 Killam Prizes, presented by the Canada Council for the Arts (Ottawa, ON), have been awarded.
|
|
May 31 2006
Ontario Government Gives $100M to Waterloo Institutes In the latest provincial budget, the Ontario government pledged $100 million to support the Institute for Quantum Computing (IQC) at the University of Waterloo (Waterloo, ON) and the Perimeter Institute for Theoretical Physics (Waterloo, ON), with each facility receiving $50 million.
|
|
May 31 2006
CTRNet Reveals New Cancer Research Tool The Canadian Tumour Repository Network (Winnipeg, MB) has announced the launch of a national tumour registry, as well as a new research infrastructure network designed to facilitate cancer research.
|
|
May 29 2006
Detailed HIV Images Could Benefit Research Using state-of-the-art techniques, researchers from Florida State University (Tallahassee, FL) have created 3-D images of the HIV virus that could facilitate the development of a vaccine.
|
|
March 13 2006
Calcium Supplements Can Reduce Pregnancy Complications A study by the World Health Organization (WHO) (Geneva, Switzerland) has concluded that calcium supplements may help prevent development of pre-eclampsia and eclampsia in pregnant women.
|
|
March 02 2006
Testing Model Could Streamline Drug Discovery The hit-or-miss element of discovering drug compounds could be greatly reduced thanks to new statistical methods developed by researchers at Montreal-based McGill University.
|
|
February 13 2006
Veggies May Provide Cancer Protection Eating your vegetables may not only make your mother happy, it might also protect you against cancer, according to a recent study published in the British Journal of Cancer.
|
|
January 30 2006
New Avian Flu Vaccine Unveiled Researchers at the University of Pittsburgh (Pittsburgh, PA) have created a highly effective, genetically engineered vaccine for protection against H5N1, the virus that causes avian flu.
|
|
October 18 2005
Gene Reactivation Could Have Therapeutic Effect on Lung Cancer Reactivating a gene commonly silenced in cancer patients could lead to an effective new therapy, according to a new study.
|
|
September 27 2005
Study Links Signalling Protein to Cell Migration A protein that regulates cell signalling pathways also helps control the active movement and migration of cells, according to a new study out of the University of Illinois at Chicago (UIC) (Chicago, IL).
|
|
August 08 2005
Coveted Cure By Deborah Komlos The ongoing worldwide vaccine hunt to combat the spread of HIV
|
|
July 29 2005
Poisonous Gas Could Become Treatment for Transplant Patients Carbon monoxide - which can kill a person when inhaled in large amounts - may one day save the lives of organ transplant patients, according to a recent study.
|
|
July 12 2005
Toxicity: Not a Dirty Word By Dr. David G. Barnes and Colin G. Rousseaux, PhD Innovators and therapeutic product developers in the world of biotechnology often fear the word toxicity.
|
|
January 17 2005
Leaders' Forum Reveals Need For Innovation in Health Research By The Leaders' Forum Steering Committee When 120 health research leaders gathered in Ottawa, Ont. this past fall for the two-day Leaders' Forum for Health Research in Canada, the importance of innovation - and in particular, the potential of biotechnology - emerged as a key theme.
|
|
January 13 2005
Cangene Poised For New Foray Into Recombinant Protein Market By Vincent Wright Opportunity linked to award-winning university research relationship
|
|
November 01 2004
Down Syndrome Cause Questioned A recently published study contradicts what researchers previously thought was a critical factor in Down syndrome.
|
|
October 16 2004
New Test for Lung Disorder By Mark D. Uehling, Bio-IT World Six months. That's how long Laboratory Corp. of America® Holdings (LabCorp®) (Burlington, NC) needed for a fast-track project to develop a DNA test for the main risk factor that leads to chronic obstructive pulmonary disease (COPD).
|
|
October 11 2004
Benefits of Beer Drinking a glass of beer may be as healthful as consuming red wine, according to the results of a recent study.
|
|
September 27 2004
Predicting Risk of SIDS SIDS, or sudden infant death syndrome, is only one among a slew of concerns that face new parents.
|
|
September 13 2004
Study Results Question Value of PSA Test A study conducted by researchers at the Stanford University School of Medicine (Stanford, CA) indicates that the PSA test, a common prostate cancer-screening tool, reveals only the size of the prostate gland, and does not predict cancer risk.
|
|
August 30 2004
$3.1M from OCRN for Seven Cancer Research Projects By Patricia Nicholson Seven cancer researchers based in Toronto, Ont. received a total of more than $3 million in funding from the Ontario Cancer Research Network (OCRN) (Toronto, ON) last week. The projects all focus on the development of new oncology treatments.
|
|
August 23 2004
New Gene Therapy Technique May Prevent Heart Attack Damage A novel gene therapy may increase survival rates of heart attack patients and prevent damage caused by heart attacks.
|
|
August 03 2004
Gene Variations Have Women Seeing Red Has something got you seeing red? Perhaps it's not that youre frustrated - but that you're a woman!
|
|
July 19 2004
Gene Variations Have Women Seeing Red Has something got you seeing red? Perhaps it's not that you're frustrated - but that you're a woman!
|
|
June 16 2004
Drug Development and Approval: Can Faster be Better? By Dr. David G. Barnes There is no question that the era of the blockbuster drug is drawing to a close. We are told that small molecule pipelines are drying up and that biotechnology will come to the rescue.
|
|
June 14 2004
Cloned Cows May be BSE-free BSE-free cows are coming, say researchers from Japan and the U.S., who anticipate birth of the calves early next year.
|
|
May 13 2004
Academics Want Collaboration with Pharma By Kevin Davies Scientists from academia and big pharma stressed chemical genomics and mutual collaboration as two of the keys to the future of drug discovery at the Human Genome Meeting 2004, held April 4-7 in Berlin, Germany.
|
|
March 22 2004
Largest Map of Cellular Protein Components Published by McGill Researchers Montreal researchers have published the most comprehensive map of the cellular machinery involved in controlling nutrient and other molecule entry into cells.
|
|
March 08 2004
Molecular Snipers Aim at Multiple Targets Thwarted in their goal of finding "smart drugs" that obliterate tumours with a single shot, oncologists are turning instead to compounds that hit multiple targets simultaneously.
|
|
January 12 2004
The Regulation of Stem Cell Research in Canada In recent times there have been efforts to impose new requirements with respect to stem cell research. Essentially, stem cells are precursor cells - ones that can differentiate into more specialized cells when signalled to do so.
|
|
November 01 2003
Clinical Trials in Canada What should we do if we want more of them?
|
|
November 01 2003
Formulation and Instability of Biotechnology Products The development of pharmaceutical products made through the use of biotechnology has significantly affected the development of processes for purification, formulation and stabilization.
|
|
October 01 2003
Countering Bugs Infectious diseases research: building basics to tackle complex problems
|
|
October 01 2003
Building Blockbuster Potential New life for old molecules
|
|
June 01 2003
A New Approach to Stroke Treatment Research collaboration targets stem cells for brain repair
|
|
April 01 2003
Celebrating the Double Helix Key figures in biotechnology reflect on the significance of the DNA 50th anniversary
|
